Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited is a leading global, research-driven biopharmaceutical company headquartered in Tokyo, Japan. Founded in 1781, Takeda has grown from a traditional Japanese medicine business into one of the world's largest pharmaceutical companies, with operations in more than 80 countries and regions.
The company focuses on developing and delivering innovative medicines in key therapeutic areas including oncology (cancer), rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines. Takeda emphasizes scientific innovation, patient-centered care, and sustainable growth to address unmet medical needs worldwide.
Takeda Pharmaceutical Company is making headlines in Japan and globally in 2026 due to a major corporate leadership transition, a massive restructuring and cost-cutting program, and high-stakes late-stage drug pipeline updates, including review milestones for its novel narcolepsy treatment, oveporexton.
“Takeda is reinforcing its global leadership through strategic transformation, operational efficiency, and a robust late-stage drug pipeline.”
Oveporexton
Mechanism of Action: Orexin receptor type 2 agonists Drug Class: Small molecules Indication: Narcolepsy
Approved: In 2026, ORZEYFUL™ (oveporexton) was approved for treating narcolepsy type 1 in adults, receiving approval in China in July and U.S. FDA approval in August. Financial impact: Takeda's oveporexton (Orzeyful) is under regulatory review in Japan and the U.S., with projected peak global sales of US$2–3 billion, making it a key driver of the company's future revenue growth.
Takeda's late-stage pipeline is led by Oveporexton (Orzeyful), a first-in-class therapy for narcolepsy type 1 currently under regulatory review in Japan and the U.S. With projected global peak sales of US$2–3 billion, the therapy is expected to become a key driver of the company's long-term revenue growth while helping offset declining sales from older products.
Takeda’s Oveporexton Poised to Transform Narcolepsy Care and Fuel Long-Term Growth
Takeda’s oveporexton (marketed as Orzeyful) is expected to be a significant long-term growth driver for the company. Takeda projects global peak sales of $2-3 billion, positioning the therapy to help offset anticipated revenue erosion from biosimilar competition affecting established products such as Entyvio.
Developed by Takeda Pharmaceuticals, oveporexton is a first-in-class oral orexin receptor 2 agonist that is reshaping Japan’s pharmaceutical landscape. In 2026, the therapy gained key approval recommendations from Japan’s Ministry of Health, Labour and Welfare (MHLW) under the Sakigake designation, highlighting its innovative potential and accelerating its path to commercialisation.
Unlike conventional narcolepsy treatments that primarily manage symptoms, oveporexton addresses the underlying orexin deficiency associated with narcolepsy type 1. This novel mechanism represents a significant advance in rare-disease treatment, shifting the focus from symptom control to targeting the root biological cause of the disease. Additionally, its progress through Japan’s priority review framework underscores the country's commitment to fast-tracking breakthrough therapies and supporting innovative domestic drug development.
“Projected to achieve $2-3 billion in peak sales, Orzeyful represents both therapeutic innovation and strategic growth for Takeda.”
"The global narcolepsy market grew from $2.68 billion in 2020 to $4.40 billion in 2025 and is expected to continue expanding in 2026, supported by breakthrough therapies and a projected CAGR of 7.9%-9.6%.”
Narcolepsy Market Growth (2020-2026)
The global narcolepsy therapeutics market has demonstrated steady growth over the past six years, increasing from $2.68 billion in 2020 to $4.40 billion in 2025. This represents an overall increase of approximately 64%, driven by greater disease awareness, improved diagnosis rates, and the launch of innovative therapies targeting excessive daytime sleepiness and cataplexy. Market revenue rose consistently from $3.0 billion in 2021, $3.2 billion in 2022, $3.57 billion in 2023, and $4.05 billion in 2024, reflecting sustained demand for advanced treatment options.
Looking ahead, the narcolepsy market is projected to maintain its growth momentum in 2026, with revenues expected to remain above $4.4 billion and rise further as next-generation therapies enter key markets. Innovative treatments such as oveporexton (Orzeyful) are anticipated to expand the market by addressing the underlying biology of narcolepsy rather than solely managing symptoms. Industry forecasts project a compound annual growth rate (CAGR) of approximately 7.9% to 9.6% through the decade, underscoring strong commercial potential and continued innovation in the narcolepsy treatment landscape.
Seven-year market revenue of Nacrolepsy drugs (2020-2026)
Fig 2: Market revenue of Nacrolepsy drugs
Takeda Revenue Performance (2020-2025)
Takeda has maintained strong annual revenues over the past six years, with revenue increasing from $29.25 billion in 2020 to a peak of $31.76 billion in 2022. Revenue remained resilient thereafter, reaching $30.4 billion in 2023, $30.2 billion in 2024, and $29.8 billion in 2025. This stable performance reflects the strength of Takeda's diversified portfolio despite growing competitive pressures and the anticipated impact of biosimilars on mature products.
Looking ahead, Takeda is positioning innovative therapies such as oveporexton (Orzeyful) to support future growth. While the company has highlighted the significant long-term commercial potential of the therapy, it stated that the initial regulatory approvals of oveporexton in the United States and China are not expected to materially change its consolidated financial outlook for the fiscal year ending March 31, 2027. Nevertheless, oveporexton is widely viewed as a strategic asset with the potential to contribute meaningfully to Takeda's long-term revenue growth as global adoption expands.
"Takeda generated annual revenues of approximately $29.8-31.8 billion between 2020 and 2025, with innovative therapies such as Orzeyful expected to support future growth despite no immediate impact on FY2027 financial forecasts."
Six-year market revenue of Takeda (2020-2025)
Fig 3: Market revenue of Takeda
Takeda's Consolidated Development Pipeline Highlights
Takeda's pipeline comprises more than 30 development programs across gastrointestinal diseases, neuroscience, oncology, plasma-derived therapies, and partnered assets, with several late-stage and filed candidates positioned to support future growth and innovation.
Gastrointestinal & Inflammation
Takeda's Gastrointestinal & Inflammation pipeline remains one of its largest growth areas, with multiple late-stage programs targeting chronic immune-mediated diseases. Key assets include zasocitinib across Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, vitiligo, and hidradenitis suppurativa, alongside mezagitamab for IgA nephropathy and immune thrombocytopenia (ITP), and fazirsiran for alpha-1 antitrypsin deficiency (AATD) liver disease. The company is also expanding the ENTYVIO franchise into pediatric indications, reinforcing its leadership in inflammatory bowel disease treatment.
Neuroscience
Takeda continues to strengthen its neuroscience portfolio through innovative orexin-based therapies. The pipeline includes TAK-360 for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, as well as TAK-495, an orexin receptor agonist in early development. These programs build on Takeda's expertise in sleep disorders and aim to address the underlying biological mechanisms of neurological conditions.
Oncology
Oncology remains a strategic focus area, supported by a broad portfolio of programs targeting both hematologic malignancies and solid tumors. Key late-stage assets include elritercept for myelofibrosis-related anemia and myelodysplastic syndromes (MDS), TAK-921 for gastric cancer, TAK-928 for lung cancer, and mirvetuximab for ovarian cancer. The pipeline is further strengthened by several early-stage solid tumor programs and regulatory filings, highlighting Takeda's commitment to expanding its oncology presence globally.
Plasma-Derived Therapies
Takeda's plasma-derived therapies portfolio focuses on rare and immune-mediated diseases. Major programs include treatments for chronic inflammatory demyelinating polyneuropathy (CIDP), primary immunodeficiency (PID), secondary immunodeficiency (SID), and direct oral anticoagulant (DOAC) reversal. The company is also advancing immunoglobulin therapies for autoimmune encephalitis in Japan, supporting its leadership in rare disease and specialty care markets.
Partnered and Strategic Assets
Takeda complements its internal pipeline through strategic partnerships and licensed assets. Notable programs include ACI-24.060 for Alzheimer's disease, IBI3001 for solid tumors, and olverembatinib for chronic-phase chronic myeloid leukemia (CP-CML). These collaborations broaden Takeda's innovation footprint and provide additional opportunities for future growth across neuroscience and oncology.
